MedCity News
AUGUST 26, 2024
With so much hinging on technology that is the subject of so much hype, it is important to understand where AI actually helps at present — and where it most definitely does not. The post The Truth About AI and Healthcare Payer Modernization appeared first on MedCity News.
Fierce Pharma
AUGUST 27, 2024
Eli Lilly has come up with a new way of supplying its popular weight-loss drug Zepbound that the company hopes could expand access while addressing other issues such as high prices and off-label co | Eli Lilly is offering its popular weight-loss drug Zepbound directly to consumers at a discount through its own online pharmacy. The company hopes the move could expand access while addressing other issues such as high prices and off-label cosmetic usage.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma IQ
AUGUST 30, 2024
Understand the potential of AI to unlock the comprehensive value of health data and transform the healthcare sector.
PharmaVoice
AUGUST 28, 2024
By rejecting the first MDMA therapy earlier this month, the FDA signaled to the psychedelic drug sector that the road to approval isn’t clear cut.
MedCity News
AUGUST 25, 2024
Health systems across the country are launching enterprise-wide deployments of AI-powered clinical documentation tools. Hospital leaders agree that this technology reduces physician burnout, as well as allows physicians to have more meaningful and productive interactions with patients. The post Which Clinical Documentation AI Tools Are Health Systems Using?
Fierce Pharma
AUGUST 29, 2024
A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer. | A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
PharmaVoice
AUGUST 27, 2024
While AI, machine learning and large language models can distill huge amounts of information, they sometimes make mistakes. New technologies could rebuild that trust.
MedCity News
AUGUST 28, 2024
Over the past decade, Abbott and Dexcom — the two largest makers of continuous glucose monitors — have been teaming up with medical device companies that sell automated insulin delivery systems. Industry experts think these partnerships are smart moves to stay relevant in the rapidly-developing diabetes care space. The post The Surprising Rivalries-Turned-Friendships That Are Shaping Diabetes Technology appeared first on MedCity News.
Fierce Pharma
AUGUST 28, 2024
The rightsizing at BioMarin continues to take its toll as CEO Alexander Hardy devises a new corporate strategy for the rare disease biotech. | The rightsizing at BioMarin continues to take its toll as CEO Alexander Hardy devises a new corporate strategy for the rare disease biotech.
pharmaphorum
AUGUST 26, 2024
A US government agency has hit back at a plan by Johnson & Johnson to change the way it pays discounts on drugs to hospitals in the controversial 340B programme
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Commerce
AUGUST 28, 2024
Session uncovers distributors’ experiences with the Waiver, Exception, or Exemption request process, and how these affect the overall supply chain.
MedCity News
AUGUST 30, 2024
Providers should carefully evaluate how different AI models can be strategically integrated to optimize the care management lifecycle and address the complex needs of their patients and populations, while at the same time prioritizing patient safety and ethical considerations. The post Overcoming the Challenges of Integrating AI in Care Management appeared first on MedCity News.
Fierce Pharma
AUGUST 30, 2024
As a new deadly strain of mpox continues its global spread, Emergent BioSoultion's smallpox vaccine ACAM2000 has officially joined the ranks of FDA-approved defense measures against the virus. | With the nod, Emergent's vaccine joins Bavarian Nordic's Jynneos as approved protection options to address the continued outbreak in Africa, which was recently deemed a public health emergency.
pharmaphorum
AUGUST 30, 2024
Emergent BioSolutions has been given FDA approval to extend the indications for its smallpox vaccine ACAM2000 to include the prevention of mpox, currently deemed a public health emergency by the WHO.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
PharmaTech
AUGUST 26, 2024
In a 24-week study of patients with PAH, six-minute walking distance improved by an average of 40.8 meters, and risk of death or clinical worsening was reduced by 82%.
MedCity News
AUGUST 28, 2024
To address the complicated healthcare landscape in the U.S., Pfizer launched a new direct-to-consumer virtual service called PfizerForAll. It follows Eli Lilly, which launched a similar product in January. The post Why Pfizer Is Dipping Into DTC Telehealth With PfizerForAll appeared first on MedCity News.
Fierce Pharma
AUGUST 27, 2024
For the last 40 years, when federal legislation was ambiguous or left an administrative gap, courts were required to defer to the interpretation of federal agencies. | In June, when the Supreme Court voted 6-3 to overturn the Chevron doctrine, it brought significant impact for the healthcare industry and federal regulators like the FDA and the Centers for Medicare & Medicaid Services.
pharmaphorum
AUGUST 28, 2024
The £400m pledged by industry as part of the new VPAG voluntary scheme of pharma rebates will be used mainly to support the UK clinical research sector
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
PharmaTech
AUGUST 26, 2024
Opaganib was given orphan drug designation for the treatment of neuroblastoma in children, which is rare, but the most common infancy malignancy.
MedCity News
AUGUST 25, 2024
Educational materials that are relatable and personalized can increase engagement. Here’s what is needed to create educational materials that empower patients and lead to better outcomes. The post Healthcare Needs to Be Proactive, Not Reactive — How Patient Education Improves Outcomes appeared first on MedCity News.
Fierce Pharma
AUGUST 29, 2024
Despite competing against several drugs that have been approved to fend off migraine headaches, AbbVie’s Ubrelvy (ubrogepant) —which is approved only to treat them—has carved out a significant nich | Recent trial results indicate that AbbVie's migraine treatment Ubrelvy works as a preventative. In a study published this week in the journal Neurology, Ubrelvy was 73% more effective in preventing a migraine attack than placebo.
pharmaphorum
AUGUST 27, 2024
J&J's Balversa has been approved in the EU for advanced bladder cancer with FGFR3 genetic alterations after one line of prior therapy
Pharmaceutical Technology
AUGUST 30, 2024
US Congress labelled pharmacy benefit managers (PBMs) as ‘anticompetitive’; PBMs blame manufacturers for increasing pharmaceutical prices.
MedCity News
AUGUST 29, 2024
Monica Vajani, Executive Director for mHUB’s MedTech Accelerator, discusses how mHUB is helping innovators transition healthcare towards value-based care. The post The Promise of Value-Based Care and MedTech Innovation appeared first on MedCity News.
Fierce Pharma
AUGUST 30, 2024
Hutchmed, the original developer of Takeda’s Fruzaqla, has decided not to pursue an approval for the VEGFR inhibitor in stomach cancer for now in its home country. | Hutchmed, the original developer of Takeda’s Fruzaqla, has decided not to pursue an approval for the VEGFR inhibitor in stomach cancer in its home country for now thanks to doubts around patients’ overall survival.
pharmaphorum
AUGUST 29, 2024
Shares in Neurocrine Biosciences took a tumble after it reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Pharmaceutical Commerce
AUGUST 29, 2024
Panel offers suggestions on how compliance teams should be considering handling SOPs, stabilization, and much more.
MedCity News
AUGUST 26, 2024
Automation startup Qventus launched a new AI assistant designed to alleviate healthcare staff’s administrative burden by completing mundane tasks for them. The assistant was built in collaboration with health systems, including Northwestern Medicine, Ardent Health and Allina Health. The post Why Northwestern Is Using Qventus’ New AI Assistant appeared first on MedCity News.
Fierce Pharma
AUGUST 28, 2024
Novartis has formed a strategic collaboration with drug delivery specialist Lindy Biosciences to develop self-administered versions of the Swiss pharma’s innovative drugs. | Novartis has formed a strategic collaboration with drug delivery specialist Lindy Biosciences to develop self-administered versions of the Swiss pharma’s innovative drugs.
pharmaphorum
AUGUST 29, 2024
Digital health firm Curio raises $10m+ in first-round financing that will be used to fund the rollout of its MamaLift Plus app for postpartum depression
Advertiser: ZoomInfo
In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.
Expert insights. Personalized for you.
111 
Let's personalize your content